Zifaxaban is an orally active, competitively and selective Factor Xa (FXa) inhibitor with an IC50 of 11.1 nM for human FXa. Zifaxaban shows >10000-fold greater selectivity than other serine proteases. Zifaxaban can be used for the arterial and venous thrombosis research.
In venous thrombosis models in rats, Zifaxaban strongly suppresses thrombus formation with ED50 values of 3.09 mg/kg, and its best efficacy time occurred at 2 h after administration[1].
In arteriovenous-shunt thrombosis and carotid thrombosis models in rats, Zifaxaban inhibits thrombus formation in a dose-dependent manner[1].
References:
[1]. Qiu X, et al. Pre-clinical pharmacodynamic study of a novel oral factor Xa inhibitor zifaxaban. Eur J Pharmacol. 2018 Oct 5;836:50-56.